Meagre medicine cabinet leaves Sanofi unloved
FRANKFURT — Sanofi’s recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines. Chief Executive Paul Hudson is entering his fourth year at the helm next month and has presided over a number of setbacks, most recently the failure of breast cancer pill amcenestrant, […]
Meagre medicine cabinet leaves Sanofi unloved
FRANKFURT — Sanofi’s recent stock rout underscores the pressure on the French drug maker to redouble its efforts in the hunt for new medicines. Chief Executive Paul Hudson is entering his fourth year at the helm next month and has presided over a number of setbacks, most recently the failure of breast cancer pill amcenestrant, […]